Edgewise Therapeutics, Inc.

NasdaqGS EWTX

Edgewise Therapeutics, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -124.29 M

Edgewise Therapeutics, Inc. Net Income is USD -124.29 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -48.56% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Edgewise Therapeutics, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -83.66 M, a -40.45% change year over year.
Edgewise Therapeutics, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -59.57 M, a -63.38% change year over year.
Edgewise Therapeutics, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -36.46 M.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

NasdaqGS: EWTX

Edgewise Therapeutics, Inc.

CEO	Dr. Kevin Koch Ph.D.
IPO Date	March 26, 2021
Location	United States
Headquarters	3415 Colorado Avenue
Employees	108
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Key trends

Past 5 years